Journal Scans
Trabectedin Plus Pegylated Liposomal Doxorubicin in Relapsed Ovarian Cancer Delays Third-Line Chemotherapy and Prolongs the Platinum-Free Interval
Longer Platinum-Free Interval Improves Survival in Ovarian Cancer
SB Kaye, N Colombo, BJ Monk, S Tjulandin, B Kong, M Roy, S Chan, E Filipczyk-Cisarz, H Hagberg, I Vergote, C Lebedinsky, T Parekh, P Santabárbara, YC Park, A Nieto, A Poveda
20100619
2010 Jul 19
Ann Oncol
Trabectedin Plus Pegylated Liposomal Doxorubicin in Relapsed Ovarian Cancer Delays Third-Line Chemotherapy and Prolongs the Platinum-Free Interval
Ann Oncol. 2010 Jul 19;[Epub Ahead of Print], SB Kaye, N Colombo, BJ Monk, S Tjulandin, B Kong, M Roy, S Chan, E Filipczyk-Cisarz, H Hagberg, I Vergote, C Lebedinsky, T Parekh, P Santabárbara, YC Park, A Nieto, A Poveda
TAKE-HOME MESSAGE
Abstract
SUMMARY
OncologySTAT Editorial Team
Trabectedin is a marine-derived antineoplastic agent active against multiple tumor types, including soft-tissue sarcoma and ovarian cancer. Combination therapy with trabectedin plus pegylated liposomal doxorubicin (PLD) was found to be superior to PDL alone for patients with relapsed ovarian cancer in the open-label, multicenter, randomized, phase III OVA-301 trial. In this study, 672 patients received either PLD 30 mg/m2 followed by trabectedin 1.1 mg/m2 every 3 weeks or PLD 50 mg/m2 every 4 weeks....
